Larry Z. Liu

3.2k total citations · 1 hit paper
41 papers, 2.4k citations indexed

About

Larry Z. Liu is a scholar working on Economics and Econometrics, Surgery and Infectious Diseases. According to data from OpenAlex, Larry Z. Liu has authored 41 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Economics and Econometrics, 10 papers in Surgery and 6 papers in Infectious Diseases. Recurrent topics in Larry Z. Liu's work include Health Systems, Economic Evaluations, Quality of Life (18 papers), Pharmaceutical Economics and Policy (11 papers) and Lipoproteins and Cardiovascular Health (10 papers). Larry Z. Liu is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (18 papers), Pharmaceutical Economics and Policy (11 papers) and Lipoproteins and Cardiovascular Health (10 papers). Larry Z. Liu collaborates with scholars based in United States, China and United Kingdom. Larry Z. Liu's co-authors include Ying P. Tabak, Marin H. Kollef, Vikas Gupta, Andrew F. Shorr, R.S. Johannes, Aaron Killian, Robert J. Straka, Sonja Sorensen, Hemant Phatak and Andreas Kuznik and has published in prestigious journals such as CHEST Journal, Critical Care Medicine and International Journal of Cancer.

In The Last Decade

Larry Z. Liu

40 papers receiving 2.3k citations

Hit Papers

Epidemiology and Outcomes of Health-care–Associated Pneum... 2005 2026 2012 2019 2005 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Epidemiology and Outcomes of Health-care–Associated Pneumonia
    2005 721 citations Marin H. Kollef, Andrew F. Shorr et al. CHEST Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Larry Z. Liu United States 24 757 540 501 407 351 41 2.4k
Richard Platt United States 18 442 0.6× 285 0.5× 519 1.0× 282 0.7× 378 1.1× 29 2.5k
Patrick D. Mauldin United States 29 673 0.9× 137 0.3× 289 0.6× 267 0.7× 465 1.3× 145 3.4k
Joseph J. Bander United States 10 770 1.0× 665 1.2× 330 0.7× 233 0.6× 417 1.2× 25 3.6k
Melissa Saul United States 40 1.3k 1.8× 496 0.9× 768 1.5× 233 0.6× 697 2.0× 145 5.5k
Brian H. Nathanson United States 32 1.2k 1.6× 693 1.3× 265 0.5× 123 0.3× 434 1.2× 159 3.5k
Xavier Corbella Spain 30 903 1.2× 371 0.7× 414 0.8× 169 0.4× 412 1.2× 153 3.6k
George R. Bailie United States 33 305 0.4× 134 0.2× 330 0.7× 311 0.8× 216 0.6× 138 4.3k
Nadine Shehab United States 27 639 0.8× 149 0.3× 256 0.5× 603 1.5× 986 2.8× 42 5.1k
Alpesh Amin United States 36 523 0.7× 244 0.5× 495 1.0× 345 0.8× 2.0k 5.8× 257 5.3k
Raymund Dantes United States 18 1.7k 2.2× 576 1.1× 590 1.2× 64 0.2× 95 0.3× 33 2.7k

Countries citing papers authored by Larry Z. Liu

Since Specialization
Citations

This map shows the geographic impact of Larry Z. Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Larry Z. Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Larry Z. Liu more than expected).

Fields of papers citing papers by Larry Z. Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Larry Z. Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Larry Z. Liu. The network helps show where Larry Z. Liu may publish in the future.

Co-authorship network of co-authors of Larry Z. Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Larry Z. Liu. A scholar is included among the top collaborators of Larry Z. Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Larry Z. Liu. Larry Z. Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Gordon G., Haijing Guan, Nan Peng, et al.. (2024). Key Issues of Economic Evaluations for Health Technology Assessment in China: A Nationwide Expert Survey. Value in Health. 27(11). 1535–1543. 4 indexed citations
2.
3.
Stevens, Warren, Desi Peneva, Jim Z. Li, et al.. (2016). Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China. BMC Health Services Research. 16(1). 175–175. 77 indexed citations
4.
Lip, Gregory Y.H., Stephen Mitchell, Xianchen Liu, et al.. (2015). Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. International Journal of Cardiology. 204. 88–94. 67 indexed citations
5.
Kamae, Isao, Yoichiro Hashimoto, Yukihiro Koretsune, et al.. (2015). Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan. Clinical Therapeutics. 37(12). 2837–2851. 22 indexed citations
6.
Kim, Christopher, Robert S. Chapman, Wei Hu, et al.. (2014). Smoky coal, tobacco smoking, and lung cancer risk in Xuanwei, China. Lung Cancer. 84(1). 31–35. 50 indexed citations
7.
Lip, Gregory Y.H., Thitima Kongnakorn, Hemant Phatak, et al.. (2014). Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation. Clinical Therapeutics. 36(2). 192–210.e20. 73 indexed citations
8.
Chapman, Robert S., Xingzhou He, Wei Hu, et al.. (2013). History of lung disease and risk of lung cancer in a population with high household fuel combustion exposures in rural China. Lung Cancer. 81(3). 343–346. 26 indexed citations
9.
DeKoven, Mitch, Nilesh Goswami, John Vincent, et al.. (2013). Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial. International Journal of General Medicine. 6. 647–647. 8 indexed citations
10.
Bosworth, Hayden B., Bradi B. Granger, Phil Mendys, et al.. (2011). Medication adherence: A call for action. American Heart Journal. 162(3). 412–424. 316 indexed citations
11.
Foody, JoAnne M., Amie T. Joyce, Barrett W. Jeffers, Larry Z. Liu, & Joshua S. Benner. (2008). A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in diabetic patients without prior cardiovascular disease. Diabetes Research and Clinical Practice. 82(1). e13–e15. 1 indexed citations
12.
Lan, Qing, Xingzhou He, Minxue Shen, et al.. (2008). Variation in lung cancer risk by smoky coal subtype in Xuanwei, China. International Journal of Cancer. 123(9). 2164–2169. 68 indexed citations
13.
Hess, Gregory P., Kafi N. Sanders, Jerrold Hill, & Larry Z. Liu. (2007). Therapeutic dose assessment of patient switching from atorvastatin to simvastatin.. PubMed. 13 Suppl 3. S80–5. 23 indexed citations
14.
15.
Straka, Robert J., et al.. (2007). Economic impacts attributable to the early clinical benefit of atorvastatin therapy – a US managed care perspective. Current Medical Research and Opinion. 23(7). 1517–1529. 9 indexed citations
16.
Shorr, Andrew F., et al.. (2006). Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Critical Care. 10(3). R97–R97. 130 indexed citations
17.
Shorr, Andrew F., Ying P. Tabak, Aaron Killian, et al.. (2006). Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database*. Critical Care Medicine. 34(10). 2588–2595. 210 indexed citations
18.
Mullins, C. Daniel, Andreas Kuznik, Fadia T. Shaya, et al.. (2006). Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Clinical Therapeutics. 28(8). 1184–1198. 33 indexed citations
19.
Kollef, Marin H., Andrew F. Shorr, Ying P. Tabak, et al.. (2005). Epidemiology and Outcomes of Health-care–Associated Pneumonia. CHEST Journal. 128(6). 3854–3862. 721 indexed citations breakdown →
20.
Shorr, Andrew F., Ying P. Tabak, Vikas Gupta, et al.. (2004). The Burden of Methicillin Resistant Staphylococcus aureus in Ventilator-Associated Pneumonia. CHEST Journal. 126(4). 716S–716S.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard Platt Breakdown of academic impact, for papers by Patrick D. Mauldin Breakdown of academic impact, for papers by Joseph J. Bander Breakdown of academic impact, for papers by Melissa Saul Breakdown of academic impact, for papers by Brian H. Nathanson Breakdown of academic impact, for papers by Xavier Corbella Breakdown of academic impact, for papers by George R. Bailie Breakdown of academic impact, for papers by Nadine Shehab Breakdown of academic impact, for papers by Alpesh Amin Breakdown of academic impact, for papers by Raymund Dantes
Rankless by CCL
2026